Fluorouracil News and Research

RSS
Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.
Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris commences perifosine Phase 3 registration trial

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Obesity linked to increased risk of cancer recurrence and death

Obesity linked to increased risk of cancer recurrence and death

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Histone modifications associated with pancreatic cancer development and progression

Histone modifications associated with pancreatic cancer development and progression

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Final data from Poniard Pharmaceuticals' randomized Phase 2 trial of picoplatin announced

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Librax AG version launched by Oceanside Pharmaceuticals

Librax AG version launched by Oceanside Pharmaceuticals

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced